CompletedNot Applicable

Regulatory Post-Marketing Surveillance of Xolair® for Chronic Rhinosinusitis With Nasal Polyps

South Korea135 participantsStarted 2023-01-12

Plain-language summary

This study aims to evaluate the safety and effectiveness of Xolair® in patients with chronic rhinosinusitis with nasal polyps in routine clinical practice.

Who can participate

Age range18 Years – 100 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Adults aged ≥18 years
✓. Patients with CRSwNP who are not adequately controlled with conventional therapy (INCS)
✓. Patients prescribed with Xolair® as per the locally approved label information.
✓. Patients who provide written informed consent to participate in the study

Exclusion criteria

✕. Patients who do not provide consent to participate in the study
✕. Patients participating in other clinical trial
✕. Contraindications listed in the locally approved label information of Xolair®

What they're measuring

Incidences of adverse events/adverse drug reactions (AEs/ADRs)

Timeframe: Up to 24 weeks

Trial details

NCT IDNCT05626257

SponsorNovartis Pharmaceuticals

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2025-04-15

View on ClinicalTrials.gov More Chronic Rhinosinusitis With Nasal Polyps trials